Image 5_Phage (cocktail)-antibiotic synergism: a new frontier in addressing Klebsiella pneumoniae resistance.tif حسب Chandrasekar Karthika (21255878)

"…<p>Phages, which play a crucial role in regulating bacterial populations and evolution, have gained renewed attention as potential therapeutic agents especially in the face of rising antimicrobial resistance, such as in Klebsiella pneumoniae– a MDR pathogen with significant clinical implications for immunocompromised individuals. …"

Table 2_Phage (cocktail)-antibiotic synergism: a new frontier in addressing Klebsiella pneumoniae resistance.doc حسب Chandrasekar Karthika (21255878)

"…<p>Phages, which play a crucial role in regulating bacterial populations and evolution, have gained renewed attention as potential therapeutic agents especially in the face of rising antimicrobial resistance, such as in Klebsiella pneumoniae– a MDR pathogen with significant clinical implications for immunocompromised individuals. …"

Image 3_Phage (cocktail)-antibiotic synergism: a new frontier in addressing Klebsiella pneumoniae resistance.tif حسب Chandrasekar Karthika (21255878)

"…<p>Phages, which play a crucial role in regulating bacterial populations and evolution, have gained renewed attention as potential therapeutic agents especially in the face of rising antimicrobial resistance, such as in Klebsiella pneumoniae– a MDR pathogen with significant clinical implications for immunocompromised individuals. …"

Image 6_Phage (cocktail)-antibiotic synergism: a new frontier in addressing Klebsiella pneumoniae resistance.tif حسب Chandrasekar Karthika (21255878)

"…<p>Phages, which play a crucial role in regulating bacterial populations and evolution, have gained renewed attention as potential therapeutic agents especially in the face of rising antimicrobial resistance, such as in Klebsiella pneumoniae– a MDR pathogen with significant clinical implications for immunocompromised individuals. …"

Image 2_Phage (cocktail)-antibiotic synergism: a new frontier in addressing Klebsiella pneumoniae resistance.tif حسب Chandrasekar Karthika (21255878)

"…<p>Phages, which play a crucial role in regulating bacterial populations and evolution, have gained renewed attention as potential therapeutic agents especially in the face of rising antimicrobial resistance, such as in Klebsiella pneumoniae– a MDR pathogen with significant clinical implications for immunocompromised individuals. …"

Table 1_Phage (cocktail)-antibiotic synergism: a new frontier in addressing Klebsiella pneumoniae resistance.xls حسب Chandrasekar Karthika (21255878)

"…<p>Phages, which play a crucial role in regulating bacterial populations and evolution, have gained renewed attention as potential therapeutic agents especially in the face of rising antimicrobial resistance, such as in Klebsiella pneumoniae– a MDR pathogen with significant clinical implications for immunocompromised individuals. …"

Image 4_Phage (cocktail)-antibiotic synergism: a new frontier in addressing Klebsiella pneumoniae resistance.tif حسب Chandrasekar Karthika (21255878)

"…<p>Phages, which play a crucial role in regulating bacterial populations and evolution, have gained renewed attention as potential therapeutic agents especially in the face of rising antimicrobial resistance, such as in Klebsiella pneumoniae– a MDR pathogen with significant clinical implications for immunocompromised individuals. …"

Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers حسب Mandeep K. Marway (21734690)

"…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …"

Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers حسب Mandeep K. Marway (21734690)

"…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …"

Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers حسب Mandeep K. Marway (21734690)

"…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …"

RBM39 methylation by PRMT6 increases RBM39 stability by inhibiting its ubiquitination. حسب Tongjia Zhang (16496661)

Baseline characteristics. حسب Daniela Sánchez-Santiesteban (21192342)

"…Lower income levels are associated with decreased survival, potentially due to delays in diagnosis or treatment and a higher probability of advanced staging at diagnosis, These inequities persist even among relatively advantaged populations, such as formal employee who are assumed to have fewer barriers to accessing healthcare services compared to informal workers.…"

LLL12B, APTO-253, and VK-1727 inhibit cell growth and induce apoptosis in LCL. حسب Huanzhou Xu (8129922)

Table 1_Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis.docx حسب Dongsheng Wu (2469307)

"…</p>Results<p>The randomized controlled trials (RCTs) included in this review examined dietary supplementation with eight polyphenols—curcumin, resveratrol, anthocyanins, quercetin, salidroside, dietary beetroot juice, pomegranate juice, and adjunctive oral AKL1 treatment—across a total of 894 participants. This systematic review and meta-analysis revealed that, compared to a placebo; ① Curcumin significantly reduced systolic blood pressure (SBP) and improved FEV1(SMD=-0.82, 95%CI -1.53 to -0.11); ② Salidroside was effective in reducing thrombotic markers (TT, D-D), inflammatory factors (TNF-α) and symptom scores (CAT) (p<0.01); ③ Resveratrol significantly downregulates serum TNF-α and IL-8 levels (p=0.003); ④ Anthocyanins may accelerate lung function decline (decreased FEV1/FVC, which needs to be interpreted with caution); ⑤ Other polyphenols (quercetin, pomegranate juice, AKL1, etc.) did not show significant efficacy or insufficient evidence. …"

Table 1_The efficacy of infliximab combined with partial enteral nutrition in the treatment of Crohn’s disease: a cohort study.docx حسب Chen Huang (202847)

"…</p>Results<p>Among the 176 included patients, 99 (56%) were in the IFX monotherapy group, and 77 (44%) were in the IFX + PEN group. A significantly higher proportion of patients in the IFX + PEN group achieved clinical response (defined as a CDAI decrease ≥70 points) compared to those in the IFX group at 14 weeks (87.01% vs. 74.75%, p = 0.043), as well as a higher proportion achieving endoscopic remission at 54 weeks (84.42% vs. 65.66%, p = 0.005). …"

Study design and plasma viral load. حسب Zoey K. Wallis (17725175)

Table 4_Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis.docx حسب Junzhe Chen (5729912)

"…Combined approaches achieved slightly lower reductions (87.31%), but significantly decreased compression dependence, improved lymphatic function, and enhanced QOL. …"

Supplementary Material for: Seizure Burden Before and After Lidocaine as Add-on Therapy in (a)EEG-Confirmed Neonatal Seizures حسب figshare admin karger (2628495)

"…After LDC administration, median TSB decreased significantly from 31 (interquartile range, IQR 16–68) to 0 minutes (IQR 0–0, p<0.01), and MSB from 10 (IQR 6–41) to 0 min/hour (IQR 0–0, p<0.01). …"

Table 3_Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis.docx حسب Junzhe Chen (5729912)

"…Combined approaches achieved slightly lower reductions (87.31%), but significantly decreased compression dependence, improved lymphatic function, and enhanced QOL. …"

Table 1_Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis.pdf حسب Junzhe Chen (5729912)

"…Combined approaches achieved slightly lower reductions (87.31%), but significantly decreased compression dependence, improved lymphatic function, and enhanced QOL. …"